Evidence map›Paper›PMID 26806301›Full record

ArticleActa pharmacologica Sinica2016

Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.

Lei-lei Ma, Zhi-tao Wu, Le Wang, Xue-feng Zhang, Jing Wang, Chen Chen, Xuan Ni, Yun-fei Lin, Yi-yi Cao, Yang Luan and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Lei-lei MaShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Zhi-tao WuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Le WangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Xue-feng ZhangJiangsu Tripod Preclinical Research Laboratories Inc, Nanjing 211800, China.
Jing WangJiangsu Tripod Preclinical Research Laboratories Inc, Nanjing 211800, China.
Chen ChenInstitute of Life Sciences, Jiangsu University, Zhenjiang 212013, China.
Xuan NiShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yun-fei LinShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Yi-yi CaoHongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Yang LuanHongqiao International Institute of Medicine, Shanghai Tongren Hospital and Faculty of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Guo-yu PanShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Chinese Academy of Sciences · CNShanghai Institute of Materia Medica · CNTongren Hospital · CNJiangsu University · CNShanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimLeflunomide is an immunosuppressive agent marketed as a disease-modifying antirheumatic drug. But it causes severe side effects, including fatal hepatitis and liver failure. In this study we investigated the contributions of hepatic metabolism and transport of leflunomide and its major metabolite teriflunomide to leflunomide induced hepatotoxicity in vitro and in vivo.

methodsThe metabolism and toxicity of leflunomide and teriflunomide were evaluated in primary rat hepatocytes in vitro. Hepatic cytochrome P450 reductase null (HRN) mice were used to examine the PK profiling and hepatotoxicity of leflunomide in vivo. The expression and function of sodium/bile acid cotransporter (NTCP) were assessed in rat and human hepatocytes and NTCP-transfected HEK293 cells. After Male Sprague-Dawley (SD) rats were administered teriflunomide (1,6, 12 mg · kg(-1) · d(-1), ig) for 4 weeks, their blood samples were analyzed.

resultsA nonspecific CYPs inhibitor aminobenzotriazole (ABT, 1 mmol/L) decreased the IC50 value of leflunomide in rat hepatocytes from 409 to 216 μmol/L, whereas another nonspecific CYPs inhibitor proadifen (SKF, 30 μmol/L) increased the cellular accumulation of leflunomide to 3.68-fold at 4 h. After oral dosing (15 mg/kg), the plasma exposure (AUC0-t) of leflunomide increased to 3-fold in HRN mice compared with wild type mice. Administration of leflunomide (25 mg·kg(-1) · d(-1)) for 7 d significantly increased serum ALT and AST levels in HRN mice; when the dose was increased to 50 mg·kg(-1) · d(-1), all HRN mice died on d 6. Teriflunomide significantly decreased the expression of NTCP in human hepatocytes, as well as the function of NTCP in rat hepatocytes and NTCP-transfected HEK293 cells. Four-week administration of teriflunomide significantly increased serum total bilirubin and direct bilirubin levels in female rats, but not in male rats.

conclusionHepatic CYPs play a critical role in detoxification process of leflunomide, whereas the major metabolite teriflunomide suppresses the expression and function of NTCP, leading to potential cholestasis.

Indexed as

AnimalsAntirheumatic AgentsCells, CulturedChemical and Drug Induced Liver InjuryCrotonatesCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemFemaleHEK293 CellsHumansHydroxybutyratesIsoxazolesLeflunomideLiverMaleMice, Inbred C57BLAntirheumatic AgentsCrotonatesCytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme SystemHydroxybutyratesIsoxazolesLeflunomideNitrilesOrganic Anion Transporters, Sodium-Dependentsodium-bile acid cotransporterSymportersteriflunomideToluidines

Identifiers

PMID26806301
PMCPMC4775851
OpenAlexW2268989250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.